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Abstract 
 
Objectives: To describe our statewide pharmacist-led, education campaign to increase 
knowledge and awareness of pneumococcal immunization recommendations.   
Setting: Immunization providers and residents in the State of Rhode Island. 
Practice description: A clinical pathway (i.e., decision-support tool) was developed to educate 
healthcare professionals about appropriate indications, administration schedules, and frequently 
asked questions for the two different adult pneumococcal vaccines.  Academic detailing and 
distribution of the clinical pathway to healthcare professionals was conducted across Rhode 
Island.  Community outreach activities included radio ads, as well as distribution of patient 
handouts and wallet cards at community events.   
Practice innovation: To our knowledge, this was the first statewide pharmacist-driven academic 
detailing and community outreach campaign to promote adult pneumococcal vaccination. 
Evaluation: Academically-detailed immunization providers received a six-question survey.  
Pneumococcal disease rate differences between the study periods were evaluated with Fisher’s 
exact tests, while changes in vaccination were assessed with chi-square tests.  
Results: From November 2013 through July 2015, our academic detailers visited and/or 
distributed our vaccination pathway materials to over 400 practice sites across Rhode Island, 
including 68% of community pharmacies and all adult acute care hospitals.  Of the 413 surveys 
completed, 92% of respondents agreed that their knowledge of the PCV13 and PPSV23 vaccines 
had improved.  Pneumococcal vaccination increased significantly (absolute difference 3.9%, 
percent change in proportion 5.4%; p=0.01) and pneumococcal disease decreased significantly 
between the pre-intervention and intervention periods (-2.74/10,000 discharges, 95% confidence 
interval [CI] -5.15, -0.32; p=0.02).  Invasive pneumococcal disease decreased by 21 cases per 
1,000,000 population per year between the pre-intervention and post-intervention periods (95% 
CI -42.25, 0.14; p=0.05).   
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Conclusion: Our statewide pharmacist-driven pneumococcal vaccination educational outreach 
program resulted in favorable provider feedback relative to knowledge change and perceptions.  
Vaccination increased while pneumococcal disease decreased during the study period. 
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Key Points 
Background 
• Pneumococcal vaccination remains well below the Healthy People 2020 goal of 90% in older 
adults, both nationally and in Rhode Island. 
• Prior to the intervention, Rhode Island had a higher burden of invasive pneumococcal disease 
than the rates observed regionally or nationally. 
• Pneumococcal vaccination recommendations have undergone several changes in recent 
years, including expanded indications for vaccination. 
Findings 
• Pharmacist-led academic detailing sessions improved self-reported immunization provider 
knowledge of PCV13 and PPVSV23 vaccination recommendations, resulting in intentions to 
apply this knowledge in clinical practice and expected changes in their vaccination practices.   
• Since implementing our academic detailing and community outreach intervention in Rhode 
Island, (1) invasive pneumococcal disease decreased despite increases in New England 
during the same time period, (2) pneumococcal vaccination increased significantly, and (3) 
there were significantly fewer pneumococcal disease hospital discharges. 
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Introduction 
More than half of pneumococcal disease in older adults occurs in non-vaccinated patients who 
have an indication for pneumococcal vaccination.1,2  Moreover, an estimated 67 million at-risk 
individuals in the United States (US) have not yet been vaccinated.1,2  This data is extremely 
concerning because patients with Advisory Committee on Immunization Practices (ACIP) 
indications for pneumococcal vaccination are twice as likely to die as those without indications if 
they develop invasive pneumococcal disease.3  Despite this grave reality, and efforts to improve 
national pneumococcal vaccination rates among populations that should be vaccinated, 
vaccinations rates rarely reach 75%.4-6  Pneumococcal vaccination in adults aged 65 years and 
older has remained relatively stable over the past several years, however, it is still well below the 
Healthy People 2020 goal of 90%.4 
 
A significant challenge with adult vaccinations, as opposed to childhood vaccinations, is 
awareness of vaccination indications among immunization providers and patients.7-10  This is 
particularly problematic in adult populations since vaccine status assessment by healthcare 
providers is not routine, patients often receive care at multiple locations (indicating care may not 
be coordinated), and patients may be unaware of their immunization status.7-10  Further, 
pneumococcal vaccination recommendations have undergone several changes in recent years 
and can be complex depending on the patient’s age, medical conditions, and previous 
pneumococcal vaccination status.11-15   
 
Objectives 
We developed a statewide pharmacist-led, education campaign utilizing academic detailing and 
patient outreach to improve adult pneumococcal rates by increasing knowledge and awareness 
of pneumococcal immunization recommendations.  To assess the effectiveness of our approach 
for improving pneumococcal vaccination in Rhode Island through education, we evaluated a 
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range of outcomes, including changes in vaccination rates, invasive pneumococcal infections, 
and pneumococcal pneumonia, as well as provider feedback on academic detailing. 
 
Setting 
Our education campaign targeted immunization providers and residents of Rhode Island.  
Immunization providers were educated in the practice setting, as well as at conferences and 
meetings.  Patients were educated at community events and through radio announcements. 
 
Practice description 
Decision pathway and educational materials   
The pharmacist-led academic detailing team developed a vaccination pathway (i.e., clinical 
decision-support tool) designed to address the complex pneumococcal vaccine administration 
schedules and corresponding indications, which served as a central component for immunization 
provider education.  The pathway was developed based on the Advisory Committee on 
Immunization Practices (ACIP) adult pneumococcal vaccination recommendations, the Center for 
Disease Control and Prevention, and the Infectious Disease Society of America (IDSA), along 
with information from the Immunization Action Coalition and prescribing information for both types 
of adult pneumococcal vaccinations (PPSV23 and PCV13; see Supplementary File, also available 
at http://web.uri.edu/antimicrobial-stewardship/infections-by-organism/).11-15  After initial pathway 
development, local infectious disease specialists were asked to provide critical analysis and 
feedback to help ensure the final pathway provided complete information in an easy-to-follow 
format.  When necessary, the pathway was updated to reflect the most current guideline 
recommendations.  The vaccination pathway was reviewed and approved by the Rhode Island 
Department of Health and copyrighted by the University of Rhode Island Office of Intellectual 
Property and Economic Development. 
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The four-page pathway document was laminated and held together by a corner ring for durability 
and accessibility in the clinical setting.  The pathway included the adult pneumococcal vaccination 
recommendations and schedule for both PPSV23 and PCV13, medical conditions requiring 
pneumococcal vaccination, facts about pneumococcal disease, frequently asked questions about 
pneumococcal vaccination, package insert information on both types of pneumococcal 
vaccinations, as well as contraindications, side effects, and precautions.  Contact information for 
the major insurance carriers in Rhode Island was also provided.  
 
A patient vaccination wallet card and pneumococcal vaccination patient information handout were 
also created.  The wallet card included space to record vaccination status for multiple adult 
immunizations and important medical information.  A wallet card sleeve was incorporated to 
protect the wallet card and included a reminder to “please carry this with you and show to your 
healthcare professional”.  The wallet card was approved by the Rhode Island Department of 
Health and the Ocean State Adult Immunization Coalition.  An educational patient handout was 
developed and included information on the dangers of pneumococcal disease, who should be 
vaccinated, and prompted patients to contact their immunization providers to get vaccinated.  The 
handout was developed using resources from the Immunization Action Coalition, the National 
Foundation for Infectious Diseases, and scholarly articles.  The wallet card, wallet card sleeve, 
and patient handout were all printed in English and in the 5 most common foreign languages 
spoken in Rhode Island since 5.7% of households in Rhode Island are linguistically isolated.   
 
Academic detailing 
Implementation, immunization providers 
In an effort to introduce our vaccination pathway to immunization providers throughout the state, 
our team (Authors JMD, KEW, KO, KLL, Group [JPB, MLC, BF, VL], Acknowledgements [TJK, 
RM, NRD]) attended 22 events with pharmacist, physicians, and nurse attendees.  Presentations 
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on our vaccination pathway were made to the Rhode Island Department of Health Flu Task Force, 
Rhode Island Certified Diabetes Outpatient Educators, Ocean State Adult Immunization Coalition, 
Wellness Company Nurses Protocol Meeting, Seminar by the Sea Northeast Regional Continuing 
Education Conference for Pharmacists, Rhode Island Pharmacists Foundation, Coastal Medical 
of Rhode Island, Rhode Island Department of Health Nurses Conference, and Economic Burden 
of Vaccine Preventable Diseases in Rhode Island.  Additionally, we mailed copies of our 
vaccination pathway to hospitals and clinics in both Rhode Island and surrounding states.  Events 
and mailings were either planned based on outreach efforts by the project team or by request of 
the event host or facility. 
 
All materials distributed during our statewide academic detailing and community outreach 
campaign were made available for download from the URI Drug Information Services website 
(http://web.uri.edu/pharmacy/drug-info/) to ensure continued access to the vaccination pathway 
and patient handouts and to make the materials available to a wider audience.  An email with the 
link to the website was sent to approximately 50 immunization providers in the state.  
 
Implementation, community pharmacies 
A list of all CVS, Rite Aid, Target, and Walgreens pharmacies in Rhode Island was compiled.  The 
URI College of Pharmacy has full-time faculty, adjunct faculty, and preceptors with clinical practice 
sites in community pharmacies across the state.  The College’s relationships with these 
pharmacies enabled us to present our pneumococcal vaccination pathway and conduct academic 
detailing at 68% (121/177) of Rhode Island pharmacies from November 2013 through July 2015.  
The academic detailers included URI faculty, a community pharmacy resident, and a student 
pharmacist.  Various academic detailing methods were used to reach as many immunization 
providers as possible in the state.  A 1-to-1, face-to-face approach was utilized at all of the CVS, 
Rite Aid, and Target pharmacy sites visited.  Sessions lasted approximately 15 minutes, and each 
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participant was provided education on how to use the pneumococcal vaccination pathway, 
vaccination indications, and the recommended schedule of vaccination.  Academic detailing for 
Walgreens pharmacies consisted of a 20-minute presentation at the Walgreens District meeting 
of 70 pharmacy managers.  Academic detailing sessions also occurred during two Rite Aid district 
meetings (23 stores).   
 
Patient outreach 
To further improve communication and coordination between patients and their immunization 
providers, a Public Service Announcement (PSA) was developed in collaboration with the Rhode 
Island Department of Health and Ocean State Adult Immunization Coalition, which aired in English 
and Spanish on Rhode Island radio stations: “Do you have diabetes or asthma?  Do you smoke?  
Are you over 65 years of age?  If you answered yes to even one of these questions, you are at 
increased risk for bacterial pneumonia.  Bacterial pneumonia is an infection of the lungs.  It’s a 
dangerous disease that could send you to the hospital.  In some cases, it can even be deadly.  
The good news is that you can protect yourself.  Ask your doctor or pharmacist about the vaccine 
that protects against bacterial pneumonia.  Vaccination - it’s your best defense.  Sponsored by 
the University of Rhode Island College of Pharmacy and the Rhode Island Department of Health”.  
Our target audience for the PSA was adults 65 years and older, and based on demographics 
provided by the advertising company, six radio stations were chosen.  The PSA aired a total of 
227 times in December 2014.   
 
To reach patients of diverse backgrounds throughout Rhode Island, the study team and the URI 
Pharmacy Outreach Program attended over 100 public health events over the intervention period.  
Events included public health fairs, such as the Feed 1,000 Rhode Islanders event for two 
consecutive years, brown bag events, support groups, and educational programs held at senior 
centers, senior housing, and community centers.  Wallet cards, patient handouts, and sticks of lip 
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balm promoting pneumococcal vaccination were distributed to attendees.  At several events, 
formal presentation about pneumococcal disease and pneumococcal vaccination were made to 
attendees.  
 
Practice innovation 
To our knowledge, this is the first statewide pharmacist-driven academic detailing and community 
outreach campaign to promote adult vaccination.  Academic detailing is “university or non-
commercial-based educational outreach which involves face-to-face education to prescribers by 
trained healthcare professionals".16,17  The goal of academic detailing is to provide education 
consistent with medical evidence and guidance documents.16,17  With the complexity of 
recommendations for pneumococcal vaccination, development of an easy-to-understand pathway 
and corresponding educational materials served as the backbone for our academic detailing 
efforts.  Prior to pathway development, implementation of the ACIP recommendations was difficult 
due to a lack of public and provider knowledge, electronic medical record systems that did not 
automatically recommend the correct vaccine, and perceived and actual financial/reimbursement 
limitations, mainly from the primary payer for older adults, Medicare. 
 
Evaluation 
Immunization provider survey 
After academic detailing sessions, each provider participant was requested to take an anonymous 
6 question survey about the effectiveness of their detailing session (see Supplementary File).  
Surveys were either submitted electronically via Survey Monkey on an iPad, or paper surveys 
were collected in a sealed envelope, depending on immunization provider preference.  Domains 
of survey measurement included content understanding, educational material ease of use, 
satisfaction with the academic detailing session, confidence in applying the new knowledge in 
practice, and intention to utilize the pathway and change vaccination practices.  Each question 
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followed a 5-point Likert scale, from strongly disagree = 1 to strongly agree = 5.  We assessed 
the percent agreeing with each question (5 = strongly agree, 4 = agree).  Health profession and 
setting were collected in the survey and question responses were compared between groups 
using the chi-square or Fisher’s exact tests as appropriate.   
 
Pneumococcal vaccination and infections 
Vaccination 
Pneumococcal vaccination was determined from the Behavioral Risk Factor Surveillance System 
(BRFSS), a national, cross-sectional survey which collects information about health behaviors, 
disease, and preventive services, such as vaccination.6,18  We evaluated the percentage of adult 
respondents 65 years and older who have ever had a pneumonia vaccination in Rhode Island 
and the US.  Percent changes in the proportion of respondents answering “yes” to this question 
over the study period were assessed, as were absolute differences.  Rhode Island BRFSS count 
data was obtained from the Rhode Island Department of Health, and US percentages were 
obtained from the Centers for Disease Control and Prevention BRFSS website. 
 
Invasive pneumococcal disease, case reports 
The goal of vaccination is to prevent morbidity and mortality, particularly invasive disease.  As 
such, we assessed changes in invasive pneumococcal disease in Rhode Island.  Invasive 
pneumococcal disease has been a reportable disease nationally since 2010.19  Invasive disease 
is confirmed by isolation of pneumococcus from blood, cerebrospinal fluid, pericardial fluid, pleural 
fluid, peritoneal fluid, joint fluid, or other normally sterile site.  Due to seasonal variations in 
pneumococcal disease, calendar years were used to define the study periods.  The pre-
intervention period was January 1 through December 31, 2013, the intervention period was 
January 1, 2014 through December 31, 2015, and the post-intervention period was January 1 
through December 31, 2016.   Due to the use of calendar years, the intervention period included 
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a 5 month wash-out period without active academic detailing or community outreach activities 
which concluded in July 2015.  Changes were compared between the pre-intervention and 
intervention periods, and pre-intervention and post-intervention periods.  We collected the number 
of cases of invasive disease from Notifiable Disease and Mortality Tables from Morbidity and 
Mortality Weekly Reports.20  Notifiable disease reports collected by individual states and territories 
are sent to the Centers for Disease Control and Prevention, which are then published as weekly 
disease rates and compiled into annual reports.20  Final reports and provisional reports were used 
to calculate cases per study period (final report for 2016 not expected until late 2017).20  
Population estimates, provided as estimates as of July 1 each year, were obtained from the United 
States Census Bureau.21   
 
Pneumococcal disease, hospital discharge data 
We assessed pneumococcal disease from hospital discharge data collected by the Rhode Island 
Department of Health.  Discharge data is captured from 5 teaching hospitals providing general 
acute care, 6 other general acute-care hospitals, 2 psychiatric teaching hospitals, and 1 
rehabilitation hospital.  International Classification of Disease, 9th revision (ICD-9) diagnosis codes 
were used to identify pneumococcal disease: pneumonia 481, bacteremia 038.2, and meningitis 
320.1.  Due to the switch from ICD-9 to ICD-10, hospital discharge data was only available through 
September 2015. 
 
Statistical analysis 
Discharge rates per 10,000 discharges and per 10,000 bed days were calculated.  Invasive 
disease was calculated per 1,000,000 population.  Using OpenEpi, changes in vaccination (for 
Rhode Island), infection type, inpatient mortality, and pneumococcal disease rate differences 
between the study periods were evaluated with chi-square, Fisher’s exact, or t-tests, as 
appropriate.22  
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Ethics approval  
This project was reviewed by the Institutional Review Board of the University of Rhode Island and 
was determined to be exempt according to federal regulations 45 CFR 46.101(b)(2) and 45 CFR 
46.101(b)(4). 
 
Results 
Academic detailing 
Academic detailing was assessed with surveys of licensed immunization providers.  Overall, 
immunization providers found the academic detailing sessions to be effective with easy to 
understand materials (Tables 1 and 2).  Most immunization providers agreed or strongly agreed 
(92%) that their knowledge of identifying which patient populations meet the recommendations 
for PCV13 or PPVSV23 improved.  Providers intended to apply the knowledge in their clinical 
practice (83%), and expected their vaccination practices to change as a result of the academic 
detailing and education materials (73%).  Almost 90% of immunization providers found the 
educational materials easy to understand.  As compared with agreement in the community setting 
(Table 1), there was significantly (p<0.05) less agreement with the questions in both the hospital 
setting (Q2-Q6) and the private practice setting (Q1, Q3-Q5).  As compared with agreement 
reported by pharmacists (Table 2), there was significantly (p<0.05) less agreement with all of the 
questions as reported by nurses. 
 
Of the 74 respondents who provided additional comments, 62% gave positive feedback regarding 
the detailer and/or materials, such as “Great flow chart, easy to read, very informative” and 
“[Academic detailer] did a great job explaining all the information! I feel that I am able to really put 
this new information into good practice.”  Of those providing positive feedback, 78% were 
pharmacists.  A quarter of the respondents providing additional comments found the pathway 
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and/or detailing session to be confusing, complicated, or lacking information (18/73), such as 
“Difficult to follow and had to flip back and forth” and “I would like a better description on the 2 
indications for Prevnar”.  Of those that found the material or session confusing, 72% were nurses.  
Other respondents noted that they do not vaccinate (3%) or were already implementing the 
pneumococcal vaccination recommendations (4%). 
 
Pneumococcal vaccination and infections 
Vaccination 
In the US, the percentage of adults 65 years and older who had ever received pneumococcal 
vaccination increased from 69.5% in 2013 to 72.5% in 2015 (absolute difference 3.0%, percent 
change in proportion 4.3%).  In Rhode Island, pneumococcal vaccination increased significantly 
from 72.4% (95% confidence interval [CI] 69.7-75.1) in 2013 to 76.3% (95% CI 73.8-78.8) in 2015 
(absolute difference 3.9%, percent change in proportion 5.4%%; p=0.01).   
 
Pneumococcal disease  
After our pharmacist-led academic detailing program, annual rates of pneumococcal disease 
declined significantly by 2.8 per 10,000 discharges (Table 3; p=0.02).  This resulted in 0.5 fewer 
bed days of care per 10,000 bed days (p=0.04).  Rates of pneumococcal disease were largely 
driven by pneumococcal pneumonia over the entire study period (79.2%).  Compared to the pre-
intervention period, the proportion of pneumococcal disease discharges in Rhode Island with 
pneumococcal pneumonia decreased significantly in the intervention period (86.0% vs 75.5%; 
p=0.01), and the proportion with pneumococcal bacteremia increased (24.3% vs 33.6%; p=0.06).  
Inpatient mortality was significantly lower in the intervention period compared to the pre-
intervention period (8.8% vs 3.6%; p=0.03). 
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Before our academic detailing program began, the annual rate of invasive pneumococcal disease 
was higher in Rhode Island (72/1,000,000 persons) than in New England (47/1,000,000 persons) 
or the United States (53/1,000,000 persons), as shown in Table 4.  While the annual rate of 
invasive pneumococcal disease increased significantly in New England over the study period 
(74/1,000,000 persons; rate difference 26.35, 95% CI 20.73, 31.98; p<0.0001), it decreased in 
both the United States (45/1,000,000 persons; rate difference -7.78, 95% CI -8.87, -6.70; 
p<0.0001) and Rhode Island (51/1,000,000 persons; rate difference -21.06, 95% CI -42.25, 0.14; 
p=0.05).  Comparing rates in Rhode Island to those in the US overall, Rhode Island had more 
cases of invasive disease per year in the pre-intervention period (rate difference 19.47, 95% CI 
3.22, 35.71; p=0.006).  In the post-intervention period, the Rhode Island rate was similar to that 
of the US (rate difference 6.19, 95% CI -7.46, 19.84; p=0.34). 
 
Discussion 
Since the implementation of our statewide academic detailing and community outreach 
intervention to increase pneumococcal vaccination among older adults, vaccination in the state 
increased significantly, and we observed other signals which infer increased vaccination, 
including a 5% decline in inpatient mortality among patient with pneumococcal disease.23-25  
Additionally, we observed significant decreases in pneumococcal disease.  Though the decline in 
invasive pneumococcal disease was at the boundary of statistical significance (p=0.05), Rhode 
Island went from having nearly 20 more cases of invasive disease per year than the overall rate 
for the United States, to having a similar rate in the post-intervention period.  Further, although 
there was a significant increase in cases of invasive pneumococcal disease in New England, we 
observed a decrease in Rhode Island. 
 
According to a recent systematic review, most academic detailing interventions have generally 
targeted one specific provider type (40.0% physician, 33.7% pharmacist, 27.4% nurse), fewer 
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studies have implemented a multifaceted approach targeting various providers (23.2%), and only 
about one third included community outreach (31.1%),.26  Further, more than half of studies only 
measured one outcome (56.6%), and a majority of those measured clinician behavior (91.5%).26  
Our intervention was multifaceted both in the intervention and measurement of outcomes.  Few 
studies have evaluated the impact of academic detailing on adult vaccinations, and fewer 
assessed the impact on actual vaccination or diseases rates.27,28  One randomized controlled 
study to increase the use of preventive services found that academic detailing and peer-
comparison feedback to physicians was no more effective in increasing influenza and 
pneumococcal vaccination than educational reminders.29   However, academic detailing has been 
effective for other medication management initiatives.30 
 
Our statewide academic detailing efforts, along with the supporting pathway and educational 
materials, impacted immunization providers’ perception of knowledge about pneumococcal 
vaccination.  Our survey results demonstrated that the academic detailing efforts increased 
immunization providers’ perceived ability to identify patients eligible for pneumococcal vaccination 
and many providers indicated that the new knowledge would be incorporated into their clinical 
practice.  Provider survey results suggests the education through academic detailing with 
supporting materials was effective for immunization providers in community settings but that 
improvements could be made in regards to hospital and nurse education. 
 
Pharmacists consistently noted the pneumococcal pathway materials assisted them and clarified 
questions they had regarding recommendations for which patient populations should receive the 
PPSV23 and PCV13 and the administration schedules.  Individual 1-to-1 approaches were mainly 
implemented to reach as many pharmacists as possible in their practice settings.  The academic 
detailers remarked on the difficulties in providing consistent academic detailing at community 
pharmacies.  Academic detailing in this setting is often challenging because of constraints on the 
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pharmacists’ time to step away from the workflow and this is dependent on prescription volume 
as well as additional professional staffing at the pharmacy.  A large group meeting of pharmacy 
managers proved to be an efficient forum, allowing pharmacists the time to adequately review the 
materials and pose questions of the detailer. 
 
Limitations 
First, national vaccination recommendations were updated over the study period and meant 
outdated materials were in circulation.  When this occurred, academic detailing was repeated in 
community pharmacies, adding considerable time to the project and effort from the academic 
detailers.  The vaccination pathway did include the URI Drug Information Services website so that 
immunization providers could access and download the most recent version of the pathway.  
Second, to account for seasonal changes in pneumococcal disease, the study periods were 
divided by calendar year, so the intervention period included a 5 month wash-out period without 
active academic detailing or community outreach activities. Though academic detailing began in 
November 2013, few sessions were conducted due to the holidays.  As immediate effects on 
statewide pneumococcal disease rates from these sessions were not expected, categorization by 
calendar year was considered appropriate.  Additionally, due to the switch from International 
Classification of Diseases 9th Edition to 10th Edition in October 2015, the codes for pneumococcal 
disease changed, and pneumococcal hospital discharges from the last quarter of 2015 onward 
were not included as rate differences may have been artefactual.  Therefore, the intervention 
period for pneumococcal hospital discharges ended in September 2015.  Third, though 
community pharmacies received two academic detailing sessions, different pharmacists may 
have participated in the detailing sessions, and as such, we were not able to follow-up with 
immunization providers to determine use of the academic detailing material in the practice or 
whether the pathways changed their immunization practices.  Fourth, we could not calculate a 
response rate for the academic detailing survey.  These results may be limited by response bias, 
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since the exact number of attendees was not known for some academic detailing sessions, and 
some pharmacists may have received academic detailing on multiple occasions.  Fifth, we 
attempted to collect vaccination data from several sources, other than BRFSS, however, we were 
not able to obtain these data.  Lastly, we were not able to control for other factors that may have 
influenced vaccination practices over time, including vaccine advertisements or internal 
immunization provider policies to increase pneumococcal vaccination.  
 
Conclusions 
Our statewide pharmacist-driven campaign to increase adult pneumococcal vaccination through 
academic detailing to immunization providers and community outreach efforts resulted in 
increased self-reported provider knowledge regarding the pneumococcal vaccine.  During the 
study period, we observed increases in vaccination and decreases in pneumococcal disease in 
Rhode Island. 
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Table 1. Immunization provider survey of academic detailing, percent agreeing or strongly 
agreeing, by setting 
 
Question Community Ambulatory 
care 
Free clinic 
N = 4 
Hospital Private 
practice  
N = 19 
Other 
N = 247 N = 24 N = 55 N = 64 
Q1. My knowledge of 
identifying which patient 
population requires 
PCV13 or PPVSV23 has 
improved 
95.5% 91.7% 100.0% 89.1% 78.9%* 82.8%* 
Q2. The educational 
material is easy to 
understand 
94.3% 100.0% 75.0% 76.4%* 89.5% 73.4%* 
Q3. This academic 
detailing session was 
effective 
96.8% 87.5% 100.0% 85.5%* 84.2%* 79.7%* 
Q4. As a result of this 
education, I am confident 
that I can apply this 
knowledge in clinical 
practice 
94.7% 87.5% 100.0% 74.5%* 73.7%* 62.5%* 
Q5. As a result of this 
education, I intend to 
apply the vaccination 
pathway in my practice 
93.9% 75.0%* 75.0% 67.3%* 73.7%* 59.4%* 
Q6. As a result of this 
education, I expect my 
82.2% 58.3%* 100.0% 60.0%* 68.4% 53.1%* 
vaccination practices to 
change 
 
* Significant (p<0.05) differences as compared with community setting.   
 
Table 2. Immunization provider survey of academic detailing, percent agreeing or strongly 
agreeing, by provider 
Question 
Pharmacist  Nurse  Nurse 
Practitioner 
N = 4 
Physician  Other  
N = 278 N = 95 N = 7 N = 29 
Q1. My knowledge of 
identifying which patient 
population requires 
PCV13 or PPVSV23 has 
improved 
96.0% 81.1%* 100.0% 71.4%* 89.7% 
Q2. The educational 
material is easy to 
understand 
96.8% 61.1%* 100.0% 100.0% 96.6% 
Q3. This academic 
detailing session was 
effective 
96.8% 72.6%* 100.0% 100.0% 100.0% 
Q4. As a result of this 
education, I am confident 
that I can apply this 
knowledge in clinical 
practice 
95.3% 65.3%* 100.0% 100.0% 55.2%* 
Q5. As a result of this 
education, I intend to 
apply the vaccination 
pathway in my practice 
91.0% 73.7%* 100.0% 85.7% 31.0%* 
Q6. As a result of this 
education, I expect my 
80.2% 64.2%* 100.0% 100.0% 24.1%* 
vaccination practices to 
change 
 
* Significant (p<0.05) differences as compared with pharmacists.   
 
 
Table 3. Change in annual rates of pneumococcal disease hospital discharges, Rhode Island 
 
Pre-
intervention 
(Jan 1, 2013 – 
Dec 31, 2013) 
Intervention 
(Jan 1, 2014 
– Sep 30, 
2015) 
Rate 
difference 
95% 
Confidence 
Interval 
Rhode Island, 
pneumococcal disease per 
10,000 discharges 
12.8 10.0 -2.74a -5.15, -0.32 
Rhode Island, 
pneumococcal disease per 
10,000 bed days 
2.5 2.0 -0.50a -0.98, -0.01 
Source: hospital discharge data. 
a Comparison of pre-intervention and intervention periods significantly different (p<0.05). 
 
Table 4. Change in annual rates of invasive pneumococcal disease 
 
Pre-
intervention 
(Jan 1, 2013 – 
Dec 31, 2013) 
Intervention 
(Jan 1, 2014 
– Dec 31, 
2015) 
Post-
intervention 
(Jan 1, 2016 
– Dec 31, 
2016) 
Pre-post rate 
difference 
95% 
Confidence 
Interval 
Rhode Island,  invasive 
pneumococcal disease per 
1,000,000 population  
72 64 51a -21.06a -42.25, 0.14 
New England, invasive 
pneumococcal disease per 
1,000,000 population 
47 76b 74c 26.35c 20.73, 31.98 
United States,  invasive 
pneumococcal disease per 
1,000,000 population 
53 49b 45c -7.78c -8.87, -6.70 
Source: Morbidity and Mortality Weekly Report data. 
a Comparison of pre-intervention and post-intervention periods, p=0.05. 
b Comparison of pre-intervention and intervention periods significantly different (p<0.05). 
c Comparison of pre-intervention and post-intervention periods significantly different (p<0.05). 
 
Pneumococcal Vaccination Outreach 
Educational Academic Detailing 
 
Which choice best describes your health profession? 
Physician Physician Assistant 
Nurse 
Practitioner Nurse Pharmacist Other 
      
 
Which choice best describes your primary workplace setting? 
Ambulatory 
care Community Free clinic 
Government 
hospital Hospital 
Private 
practice 
Other 
       
 
Please indicate your degree of agreement with each statement.  
 Strongly Agree Agree Neutral Disagree 
Strongly 
Disagree 
1. My knowledge of identifying which patient 
population requires Prevnar 13® (pneumococcal 
conjugate vaccine; PCV13) or Pneumovax® (23-
valent polysaccharide vaccine; PPVSV23) has 
improved. 
     
2. The educational material is easy to understand.      
3. This academic detailing session was effective.      
4. As a result of this education, I am confident that I 
can apply this knowledge in clinical practice.      
5. As a result of this education, I intend to apply the 
vaccination pathway in my practice.        
6. As a result of this education, I expect my 
vaccination practices to change.      
 
Comments for specific questions. 
 
 
 
 
 
 
Please use the space below to add overall comments about the academic detailing or educational materials. 
 
 
 
 
 
 
Pneumococcal Vaccination 
Naive or Unknown History
GIVE: PCV13
Wait ≥ 1 year*
GIVE: PPSV23†
Previously vaccinated with 
PPSV23 at age ≥65
≥ 1 year after PPSV23
GIVE:  PCV13 if not previously given
Wait ≥ 1 year* 
(and ≥ 5 years after PPSV23)
≥ 1 year after PPSV23
GIVE: PPSV23†
GIVE: PCV13 if not previously given
Previously vaccinated with 
PPSV23 before age 65
Vaccination is NOT
 indicated for healthy persons 
19 - 64 years of age
While PCV13 is FDA-approved for
persons > 50 years, the Advisory
Committee on Immune Practices
does not provide guidance for use
in this population.
Previously vaccinated with one 
dose PPSV23
Pneumococcal Vaccination 
Naive or Unknown History
At Age ≥65  
GIVE: PCV13 ≥ 1 year after PPSV23
THEN: PPSV23† ≥ 1 year* after 
PCV13 and ≥ 5 years after PPSV23
GIVE: PPSV23
  ADULTS ≥ 19 with IMMUNE COMPROMISING CONDITIONS (see chart on back), OR ASPLENIA
(including sickle cell anemia), CEREBROSPINAL FLUID LEAK, or COCHLEAR IMPLANT
 ADULTS ≥ 19 with UNDERLYING MEDICAL CONDITIONS (see chart on back) 
OR who SMOKE or live in a NURSING HOME
          *  Minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks in immunocompromised patients.
              For Medicare reimbursement interval must be 11 full months. Please refer to page 4.
          †  The ACIP (Advisory Committee on Immunization Practices) recommends only 1 dose of PPSV23 at age ≥65. Revaccination is not necessary.
          §  A second PPSV23 for patients with cerebrospinal fluid leak, or cochlear implant is not required.
        PPSV23=23-Valent Pneumococcal Polysaccharide Vaccine (Pneumovax®23)
        PCV13=13-Valent Pneumococcal Conjugate Vaccine (Prevnar 13®)
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Previously vaccinated with one 
dose PPSV23
≥8 weeks* later
≥ 1 year after PPSV23
GIVE: PCV13 if not previously given
Previously vaccinated with
two doses of PPSV23
≥ 1 year after PPSV23
GIVE:  PCV13 if not previously given
At Age ≥ 65 
GIVE: PPSV23† ≥ 8 weeks* after 
PCV13 and ≥ 5 years after PPSV23
 Pneumococcal Vaccination 
Naive or Unknown History
                    ≥8 weeks* later
GIVE: PCV13
  If  < 65 and 
≥ 5 years after 
PPSV23
GIVE: second 
PPSV23 §
If  < 65
GIVE: PPSV23
If  ≥65
GIVE: PPSV23
GIVE: PPSV23† At Age ≥65
GIVE: PPSV23† 
≥ 5 years after 
PPSV23
If  ≥65
GIVE: PPSV23† 
≥5 years after 
PPSV23
  If  < 65 and 
≥ 5 years after 
PPSV23
GIVE: second 
PPSV23 §
At Age ≥65
GIVE: PPSV23† 
≥ 5 years after 
PPSV23
At Age ≥65  
GIVE: PCV13 ≥ 1year after PPSV23
THEN: PPSV23† ≥ 1 year* after 
PCV13 and ≥ 5 years after PPSV23
Pneumococcal Vaccination
Recommendations
Adults ≥19 Years1-4
(Including updated recommendations for the use of PCV13 in Adults)
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pneumococcal	  Vaccina>on	  Informa>on	  Sheet	  
PCV13	  (Prevnar	  13®)	  and	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Department	  of	  Health	  State	  Supplied	  Vaccina7on	  Program	  
www.health.ri.gov/resources/immuniza>on/	  	  
Medicare	  www.medicarenhic.com	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
BCBS	  of	  RI	  	  www.bcbsri.com/providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	  www.unitedhealthcareonline.com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (Pneumovax®23)	   PCV13	  (Prevnar13®)	  
Manufacturer:	  
erck	  
www.merckvaccines.com/	  
Manufacturer:	  
Pﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Preﬁlled	  Syringe	  
(10	  per	  Package)	  
Storage	  and	  Handling:	  	  
Refrigerate	  on	  Arrival	  	  
Store	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Storage	  and	  Handling:	  
Refrigerate	  on	  Arrival	  
Store	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Special	  instruc7ons:	  	  	  
None	  
Special	  instruc7ons:	  	  
Shake	  well	  to	  obtain	  a	  homogeneous	  white	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  or	  SQ	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  ONLY	  
Contraindica>ons	  and	  Precau>ons:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  Most	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  redness	  at	  the	  injec@on	  site,	  
las@ng	  1-­‐2	  days.	  
•  Do	  not	  give	  PPSV23	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  history	  of	  a	  serious	  reac@on	  (e.g.,	  anaphylaxis)	  aYer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	  or	  one	  of	  their	  components.	  
•  Do	  not	  give	  PPSV23	  and	  PCV13	  simultaneously.	  For	  pa@ents	  who	  need	  both	  PCV13	  and	  PPSV23,	  give	  
PCV13	  ﬁrst,	  followed	  by	  a	  dose	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	  months	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
•  PCV13	  and	  PPSV23	  are	  both	  inac@vated	  vaccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  then	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  same	  visit.	  You	  cannot	  give	  PCV13	  and	  PPSV23	  simultaneously.	  
Insurance	  Carrier	  Informa>on:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pneumococcal	  V ccina>on	  Informa>on	  Sheet	  
PCV13	  (Prevnar	  13®)	  and	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Department	  of	  Health	  State	  Supplied	  V ccina7on	  Program	  
www.health.ri.g v/resourc s/immuniza>on/	  	  
Medicare	   . edicarenhic.com	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
BCBS	  of	  RI	  	  www.bcbsri.com/providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	  www.unitedh althcareonline.com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (Pneumovax®23)	   PCV13	  (Prevnar13®)	  
Manufacturer:	  
erck	  
www.merckvaccines.com/	  
Manufactu er:	  
ﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Preﬁll d	  Syringe	  
(10	  per	  Package)	  
Stor ge	  and	  Handling:	  	  
Refrigerate	  on	  Arrival	  	  
t r 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Stor ge	  and	  Handling:	  
Refrigerate	  on	  Arrival	  
tore	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Special	  inst uc7ons:	  	  	  
None	  
Special	  instruc7ons:	  	  
Shake	  well	  to	  obtain	  a	  homogeneous	  white	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  or	  SQ	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  ONLY	  
Contrai dica>ons	  and	  Precau>ons:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  M st	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  red ess	   t	  the	  injec@on	  site,	  
las@ g	  1-­‐2	  d ys.	  
•  o	  not	  give	  PPS 23	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  history	  of	  a	  serious	  reac@on	  (e.g.,	  anap ylaxis)	  aYer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	  or	  one	  of	  their	  components.	  
Do	  not	  give	  PPSV23	  and	  PCV13	  simultaneously.	  For	  pa@e ts	  who	  need	  both	  PCV13	  an 	  PPSV23,	  give	  
PC 13	  ﬁrst,	  followed	  by	  a	  dos 	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	  months	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
•  PCV13	   nd	  PPSV23	  are	  both	  inac@vated	  v ccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  then	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  sa e	  visit.	  You	  cannot	  giv 	  PCV13	  and	  PPSV23	  simultaneously.	  
Insurance	  Carrier	  Informa>on:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pne mococcal	  V ccina>on	  Informa>on	  Sheet	  
PCV13	  (Pr vnar	  13®)	  and	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Department	  of	  H alth	  State Supplied	  V ccina7on	  Program	  
www.health.ri.g v/resourc /immuniza>on/	  	  
Medicare	   edicarenhic.com	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
BCBS	  of	  RI	  	  www.bcbsri.com/pro iders	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	  www.unitedh althcareonline.com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (P umovax®23)	   PCV13	  (Prevnar13®)	  
Manufac urer:	  
e ck	  
www.merckvaccines.com/	  
Manufac u er:	  
ﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Pr ﬁll d	  Syringe	  
(10	  p r	  Package)	  
Stor ge	  an 	  Handling:	  	  
Refrigerate	  on	  Arrival	  	  
t r 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Stor ge	  an 	  Handling:	  
Refrigerate	  on	  Arrival	  
tore	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Special	  inst uc7ons:	  	  	  
None	  
Special	  instruc7ons:	  	  
Shake	  well	  to	  obt in	  a	  homogeneous	  white	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  or	  SQ	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  ONLY	  
Contrai dica>ons	  and	  Prec u>ons:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  M st	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  red ess	   t	  the	  injec@on	  site,	  
las@ g	  1-­‐2	  d ys.	  
•  o	  not	  give	  PPS 23	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  history	  of	  a	  serious	  reac@on	  (e.g.,	  anap ylaxis)	   Yer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	   r	  one	  of	  their	  components.	  
Do	  not	  giv 	  PPSV23	  and	  PCV13	  simultaneously.	  For	  pa@e ts	  wh 	  need	  both	  PCV13	  an 	  PPSV23,	  give	  
PC 13	  ﬁrst,	  followed	  by	  a	  dos 	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	  months	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
•  PCV13	   nd	  PPSV23	  are	  both	  inac@vated	  v ccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  th n	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  sa e	  visit.	  You	  can ot	  giv 	  PCV13	  and	  PPSV23	  simultaneously.	  
Insurance	  Carrier	  Inform >on:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pne m occ l	  Vaccina>on	  Informa>on	  Sh t	  
PCV13	  (Pr vnar	  13®)	  and	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Department	  of	  H alth	  State	  S pplied	  Vaccina7on	  Program	  
www.health.ri.gov/resource /immuniza>on/	  	  
Medicare	  www.medicarenhic.com	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  rei burses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
B BS	  of	  RI	  	  www.bcbsri.com/pro iders	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	  www.u itedhealthcareonline.com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (P umovax®23)	   PCV13	  (Pr vnar13®)	  
Manufacturer:	  
erck	  
www.merckvaccines.c m/	  
M nufactu er:	  
Pﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Preﬁlled	  Syring 	  
(10	  p r	  Package)	  
Storage	  and	  Handling:	  	  
Refrigerate	  on	  Arrival	  	  
Store	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Storage	  and	  Handling:	  
Refrig rate	  on	  Arrival	  
Store	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Special	  instruc7ons:	  	  	  
None	  
Special	  i struc7ons:	  	  
Shake	  w ll	  to	  obtai 	  a	  hom geneous	  white	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  or	  SQ	  
Rou e	  of	  Admi istra7 :	  	  
0.5mL	  IM	  ONLY	  
Contraindi a> ns	  and	  Prec u>ons:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  Most	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  redness	  at	  the	  injec@on	  site,	  
las@ng	  1-­‐2	  days.	  
•  Do	  not	  give	  PPSV23	  or	  PCV13	  to	  pa@e ts	  who	  have	  a	  hist ry	  of	  a	  serious	  reac@on	  (e.g.,	  anaphylaxis)	  aYer	  
	  previ us	  d se	  of	  PCV13,	  PPSV,	  or	  one	  of	  their	  comp ne ts.	  
•  Do	  not	  giv 	  PPSV23	  and	  PCV13	  simultaneously.	  For	  pa@ents	  who	  need	  both	  PCV13	  and	  PPSV23,	  give	  
PCV13	  ﬁrst,	  followed	  by	  a	  d se	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	   onths	  aYer	  the	  
m 	  recent	  do e	  of	  PPSV23.	  
•  PCV13	  and	  PPSV23	  ar 	  bo h	  inac@vated	  vaccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  w it	  4	  weeks	  and	  th n	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Me v o®)	  both	  can	  be	  given	  
at	  th 	  same	  visit.	  You	  can ot	  give	  PCV13	  and	  PPSV23	  simultaneously.	  
I surance	  C rrier	  Infor >on:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pn um occal	  V ccina>on	  Informa>on	  Sh t	  
PCV13	  (Prevnar	  13®)	  and	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Depart ent	  of	  Health	  State	  S pplied	  Vaccina7on	  Program	  
www.health.ri.g v/resourc /immuniz >on/	  	  
Medicare	   . e ic renhic.c m	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
B BS	  of	  RI	  	  www.bcbsri.com/providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	  www.u itedh althcareonlin .com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (Pn umovax®23)	   PCV1 	  (Pr vnar13®)	  
Manufacturer:	  
erck	  
www.merckvaccines.c m/	  
M nufactu er:	  
ﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Preﬁll d	  Syring 	  
(10	  per	  Package)	  
Stor ge	  and	  Handling:	  	  
Refrigerate	  on	  Arrival	  	  
t r 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  th 	  expira@on	  date	  
Stor ge	  and	  Handling:	  
Refrig rate	  on	  Arrival	  
tore	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Special	  inst uc7ons:	  	  	  
None	  
Special	  i struc7ons:	  	  
Shake	  w ll	  to	  obtai 	  a	  hom geneous	  white	  suspension	  
Route	  of	  Administra7 n:	  	  
0.5 L	  IM	  or	  SQ	  
Rou e	  of	  Admi stra7 :	  	  
0.5mL	  IM	  ONLY	  
Contrai d ca> ns	   nd	  Precau> ns:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  M st	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  red ess	   t	  the	  injec@on	  site,	  
las@ g	  1-­‐2	  d ys.	  
•  	   t	  give	   S 	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  hist ry	  of	  a	  serious	  reac@on	  (e.g.,	  anap ylaxis)	  aYer	  
a	  previ us	  d se	  of	  PCV13,	  PPSV,	  or	  one	  of	  their	  components.	  
  Do	  not	  giv 	  PPSV23	  a d	  PCV13	  simultaneously.	  For	  pa@e ts	  w o	  need	  both	  PCV13	  an 	  PPSV23,	  give	  
	  ﬁrst,	  followed	  by	  a	  d s 	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	   onths	  aYer	  the	  
m st	  recent	  dose	  of	  PPSV23.	  
•  PCV13	   nd	  PPSV23	  ar 	  bo h	  inac@vated	  v ccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  then	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  sa e	  visit.	  You	  cannot	  giv 	  PCV13	  and	  PPSV23	  simultaneously.	  
I surance	  C rrier Informa> n:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pn mo occal	  V ccin >on	  Infor a>on	  Sh t	  
PCV13	  (Pr vnar	  13®)	  and	  PPSV23	  (Pn umovax®	  23)	  	  
RI	  D part ent	  of	  H alth	  State	  Supplied	  V ccina7on	  Program	  
www.health.ri.g v/resourc /immuniz >on/	  	  
Medicare	   e ic renhi .com	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  for	  b th	  the	  cost	  of	  th 	  vaccine	  and	  its	  administraDon	  
B BS	  of	  RI	  	  www.bcbsri.com/providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	   ww.u itedh althcareonlin .com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (P umovax®23)	   PCV1 	  (Prevnar13®)	  
Manufac urer:	  
e ck	  
www.merckvaccines.com/	  
Manufac urer:	  
ﬁzer	  
www.pﬁzerpro.com/	  
How	  Supplied:	  
0.5ml	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
How	  Supplied:	  
Pr ﬁll d	  Syring 	  
(10	  p r	  Pa kage)	  
Stor ge	  an 	  Handling:	  	  
Refrigerate	   n	  Arrival	  	  
t r 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  th 	  expira@on	  date	  
Stor ge	  an 	  Handling:	  
Refrig rate	  on	  Arrival	  
tore	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	   Y 	  the	  expira@on	  date	  
Special	  inst uc7ons:	  	  	  
None	  
Spe ial	  instruc7ons:	  	  
Shake	  w ll	  to	  obt i 	  a	  homogeneous	  white	  suspensio 	  
Route	  of	  Administra7 n:	  	  
0.5 L	  IM	  or	  SQ	  
Rou e	  of	  Admin stra7on:	  	  
0.5mL	  IM	  ONLY	  
Contrai d ca> ns	   nd	  Precau> ns:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  M st	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  red ess	   t	  the	  injec@on	  site,	  
las@ g	  1-­‐2	  d ys.	  
•  	   t	  give	   S 	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  hist ry	  of	  a	  serious	  reac@on	  (e.g.,	  anap ylaxis)	   Yer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	   r	  one	  of	  their	  components.	  
  Do	  not	  giv 	  PPSV23	  a d	  PCV13	  simultaneously.	  For	  pa@e ts	  w 	  need	  both	  PCV13	  an 	  PPSV23,	  give	  
	  ﬁrst,	  followed	  by	  a	  dos 	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	  months	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
  PCV13	   nd	  PPSV23	  are	  both	  inac@vated	  v ccines.	  You	  can	  give	  all	  other	  recommended	  vaccina@on 	  at	  
the	  same	  visit	  EXCEPT	  if	  the	  person	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  th n	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  sa e	  visit.	  You	  can ot	  giv 	  PCV13	  and	  PPSV23	  simultaneously.	  
Insurance	  Carrier	  Inform > n:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pne m c ccal	  Vaccin >on	  Informa> n	   he t	  
PCV13	  (Pr vna 	  13®)	  and	  PPSV23	  (Pn umovax®	  23)	  	  
RI	  D partment	  of	  H lth	  State	  S pplied	  Vaccina7on	  Program	  
www.health.ri.gov/res rce /immuniza>on/	  	  
Medicare	  www medic r nhi .c m	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  r imburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
BCBS	  of	  RI	  	  www.bcbsri.com/providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedHealthCare	   ww.unit dhealthcareonline.com	  1-­‐877-­‐842-­‐ 210	  
	  PPSV23	  (P umovax®23)	   PCV13	  (Pr vnar13®)	  
Manufac u er:	  
ck	  
www.merckvaccines.com/	  
Manufac urer:	  
Pﬁz r	  
www.pﬁzerpr .com/	  
H w	  Supplied:	  
l	  Singl 	  Dose Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
H w	  Supplied:	  
Pr ﬁlled	  Syring 	  
(10	  p r	  Pa kage)	  
Storage	  an 	  Handling:	  	  
Refrig rate	   n	  Arrival	  	  
Store	  at	  2◦ 	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	  aYer	  the	  expira@on	  date	  
Storage	   	  Handling:	  
R friger t 	  on	  Arrival	  
S or 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Discard	   Y 	  the	  expira@on	  date	  
Spec al	  instruc7ons:	  	  	  
None	  
Spe ial	   struc7ons:	  	  
Shake	  well	  to	  obt in	   	  homogeneous	  whit 	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  or	  SQ	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	  ONLY	  
Contraindica> ns	  and	  Precau>ons:	  
	  
Side	  Eﬀects:	  
	  
Source	  of	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.preven@nﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  Most	  common	  side	  eﬀects	  from	  either	  PPSV23	  or	  PCV13	  are	  soreness	  and	  redness	  at	  the	  injec@on	  site,	  
las@ng	  1-­‐2	  days.	  
•  Do	  not	  give	  PPSV23	  or	  PCV13	  to	  pa@ents	  who	  have	  a	  history	  of	  a	  serious	  reac@on	  (e.g.,	  anaphylaxis)	   Yer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	   r	  one	  of	  their	  components.	  
  Do	  not	  giv 	  PPSV23	  a d	  PCV13	  simultaneously.	  For	  pa@ents	  w 	   ed	  bo h	  PCV13	  and	  PPSV23,	  give	  
PCV13	  ﬁrst,	  followed	  by	  a	  d se	   f	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  ad lts	  PCV13	  12	  months	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
  PCV13	  and	  PPSV23	  ar 	  b th	  inac@vated	  vaccines.	  You	  can	  give	  all	  other	  recomm ded	  vacci a@on 	  at	  
the	  same	  visit	  EXCEPT	  if	  th 	  p rson	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  th n	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  same	  visit.	  You	  can ot	  give	  PCV13	  and	  PPSV23	  simultaneously.	  
I suranc 	  Ca rier	  I fo m >on:	  
	  	  	  	  Drug	  Informa>on	  Services	  401-­‐874-­‐9188	  	  Monday-­‐Friday	  8:30	  am-­‐4:00	  pm	  EST	  
Pn m c ccal	  V ccina>on	  Informa> n	  S e t	  
PCV13	  (Pr vna 	  13®)	  and	  PPSV23	  (Pn umovax®	  23)	  	  
RI	  D part ent	  of	  H lth	  State	  S pplied	  V ccina7on	  Program	  
www.health.ri.g v/r s rc /immuniz >on/	  	  
Medicare	  w e ic r nhi .c m	  	  1-­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  r imburses	  for	  both	  the	  cost	  of	  the	  vaccine	  and	  its	  administraDon	  
BCBS	  of	  RI	  	  www.bcbsri.co /providers	  	  401-­‐274-­‐4848	  	  1-­‐800-­‐230-­‐9050	  
UnitedH althCare	   .unit dh althcareonlin .com	  1-­‐877-­‐842-­‐ 210	  
	  PPSV23	  (P umov x®23)	   PCV1 	  (Pr vnar13®)	  
Manufac urer:	  
ck	  
www.merckvaccines.com/	  
Manufac urer:	  
ﬁzer	  
www.pﬁzerpr .com/	  
H w	  Supplied:	  
l	  Single	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  dose	  Vial)	  
H w	  Supplied:	  
r ﬁll d	  Syringe	  
(10	  p r	  Pa kage)	  
Stor ge	  an 	  Handling:	  	  
Refrigerate	   n	  Arrival	  	  
t r 	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Disc rd	  aYer	  th 	  expira@on	  date	  
Stor ge	  an 	  Handling:	  
Refrig rate	  on	  Arrival	  
ore	  at	  2◦C	  to	  8◦C	  
DO	  NOT	  FREEZE	  
Disc rd	   Y 	  the	  expira@on	  date	  
pec al	  inst uc7ons:	  	  	  
N n 	  
pe ial	  i struc7ons:	  	  
hake	  well	  to	  obt in	  a	  homogeneous	  white	  suspension	  
Route	  of	  Administra7 n:	  	  
0.5 L	  IM	  o 	  SQ	  
Route	  of	  Admin stra7on:	  	  
0.5mL	  IM	  ONLY	  
Co trai d ca>ons	   nd	  Prec u> ns:	  
	  
Sid 	  Eﬀects:	  
	  
Source	   f	  informa@on;	  Immuniza@on	  Ac@on	  Coali@on	  (www.immunize.org)	  in	  collabora@on	  with	  the	  Na@onal	  Adult	  and	  I ﬂuenz 	  Immuniza@on	  Summit	  
(www.preven@nﬂuenz .org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  M st	  co mon	  side	  eﬀects	  from	   ither	  PPSV23	  or	  PCV13	  are	  soreness	  and	  red ess	   t	  the	  injec@on	  site,	  
las@ g	  1-­‐2	  d ys.	  
•  	   t	  give	   S 	  or	  PCV13	  to	  pa@ents	  wh 	  have	  a	  history	  of	  a	  serious	  reac@on	  (e.g.,	  anap ylaxis)	   Yer	  
a	  previous	  dose	  of	  PCV13,	  PPSV,	   r	  one	  of	  their	  components.	  
  	   t	  giv 	   S 	  and	  PCV13	  simulta eously.	  For	  pa@e ts	  wh 	   ed	  both	  PCV13	   n 	  PPSV23,	  give	  
	  ﬁrst,	  followed	  by	  a	  dos 	  of	  PPSV23	  at	  least	  8	  weeks	  later.	  Give	  adults	  PCV13	  12	  mont s	  aYer	  the	  
most	  recent	  dose	  of	  PPSV23.	  
  	   nd	  PPSV23	  ar 	  b th	  inac@vated	  v ccines.	  You	  ca 	  give	  all	  other	  recomm de 	  vacci a@on 	  at	  
the	  same	  visit	  EXCEPT	  if	  th 	  p rson	  is	  a	  candidate	  for	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Menactra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  th n	  give	  MCV4-­‐D.	  If	  using	  MCV4-­‐CRM	  (Menveo®)	  both	  can	  be	  given	  
at	  the	  s e	  visit.	  You	  can ot	  giv 	  PCV13	   nd	  PPSV23	  simultaneously.	  
I surance	  Ca rier	  Info m > n:	  
RH
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Pneumococcal Vaccination
Recommendations
Adults ≥19 Years
1-5
(Including updated recommendations for the use of PCV13 in Adults)
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  I f 	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13	  ( rev ar	  13®)	  a 	   S 23	  ( e vax®	  23)	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   f	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  St t 	  S li 	   cci 	   r r 	  
. lt .ri. /r s r s/i iz /	  	  
ic r 	   . ic r ic.c 	  	   -­‐ -­‐ -­‐ 	  
edi are	  Part	  B	  rei burses	  for	  both	  th 	  cost	  of	  the	  vaccine	  and	  its	  ad inistraDon	  
S	   f	   I	  	   . c sri.c / r vi rs	  	   -­‐ -­‐ 	  	   -­‐ -­‐ -­‐ 	  
it lt r 	   . it lt r .c 	   -­‐ -­‐ -­‐ 	  
	   	  ( )	   	  ( r r )	  
anufacturer:	  
erck	  
. erckvaccines.co /	  
anufacturer:	  
Pﬁzer	  
.pﬁzerpro.co /	  
o 	  Supplied:	  
0.5 l	  Sing e	   ose	   ial	  	  
ul@-­‐ ose	  (5	  dose	   ial)	  
o 	  Supplied:	  
Preﬁlled	  Syringe	  
(10	  per	  Packa )	  
Storage	  and	   andling:	  	  
Ref igerate	  on	   rrival	  	  
St e	  at	  2◦C	  to	  8◦C	  
	   T	  FREEZE	  
iscard	  a er	  the	  expira@on	  date	  
Storage	  and	   andling:	  
Ref igerate	  on	   rrival	  
St e	  at	  2◦C	  to	  8◦C	  
	   T	  FREEZE	  
iscard	  a er	  the	  expira@on	  date	  
pecial	  instruc ons:	  	  	  
one	  
pecial	  instruc ons:	  	  
hake	   ell	  t 	  obtain	  a	  ho ogeneous	   hite	  suspension	  
R ute	  of	   d inistra on:	  	  
0.5 L	  I 	  or	  S 	  
Route	  of	   d inistra on:	  	  
0.5 L	  I 	   LY	  
tr i i s	   	   s:	  
	  
i 	   ts:	  
	  
Source	  of	  infor a@on;	  I uniza@on	  Ac@on	  Coali@on	  ( .i unize. rg)	  in	  collabora@on	   ith	  the	  Na@o al	  Adult	  and	  I ﬂu nza	  I uniza@on	  Su it	  
( .prev n@nﬂuenza.org);	  accessed	  Septe ber	  4,	  2013.	   R	  2012;	  61(40):816-­‐819.	  
•  	  c 	   i 	   cts	  f 	   i r	   S 	   	   	   r 	   r ss	   	  r ss	   t	  t 	  i j c 	  sit ,	  
l s 	   -­‐ 	   ys.	  
•  	   t	   iv 	   S 	   r	   	  t 	   ts	   	   v 	   	   ist ry	   f	   	  s ri s	  r c 	  ( . .,	   yl xis)	   r	  
	   r v s	   s 	   f	   ,	   S ,	   r	   	   f	  t ir	  c ts.	  
•  	   t	   iv 	   S 	   	   	  si lt sly.	  F r	   ts	   	   	   t 	   	   	   S ,	   iv 	  
	   rst,	  f ll 	   y	   	   s 	   f	   S 	   t	   st	   	   ks	  l t r.	   iv 	   lts	   	   	   t s	   r	  t 	  
st	  r c t	   s 	   f	   S .	  
•  	   S 	   r 	   t 	  i c v t 	  v cci s.	   	  c 	   i 	   ll	   t r	  r c 	  v cci s	   t	  
t 	  s 	  visit	   	  if	  t 	   r 	  is	   	  c i t 	  f r	   	   	   .	  If	   si 	   -­‐ 	  ( ctr )	  
iv 	   	   rst,	   it	   	   k 	   	  t 	   iv 	   -­‐ .	  If	   i 	   -­‐ 	  ( v )	   t 	  c 	   	   iv 	  
t	  t 	  s 	  vi it.	   	   t	   iv 	   	   	   S 	  si l sly.	  
I s r 	   rri r	  I f r :	  
	  	  	   	  I f 	   i 	   -­‐ -­‐ 	  	   -­‐ i 	   : 	   -­‐ : 	   	   	  
l	   i 	   	   	  
	  ( r r	   )	   	   	  ( 	   )	  	  
I	   	   	   l 	   	   li 	   i 	   	  
. l . i. i i 	  	  
i 	   . i i . 	  	   -­‐ -­‐ -­‐ 	  
i r 	   rt	   	  r i rs s	  f r	   t 	  t 	   st	   f	  t 	   i 	   	  its	   i istr 	  
	   f	   I	  	   . i. i 	  	   -­‐ -­‐ 	  	   -­‐ -­‐ -­‐ 	  
i l 	   . i l li . 	   -­‐ -­‐ -­‐ 	  
	   	   	   	   	  
f t r r:	  
M r 	  
. r i s. /	  
f t r r:	  
r	  
. r r . /	  
	   li :	  
. l	   i l 	   s 	   i l	  	  
l -­‐ s 	  ( 	   s 	   i l)	  
	   li :	  
r ll 	   ri 	  
( 	   r	   )	  
t 	   	   li :	  	  
f i r t 	   	   rri l	  	  
t r 	   t	   ◦ 	  t 	   ◦ 	  
	   	   	  
is r 	   r	  t 	   ir 	   t 	  
t 	   	   li :	  
f i r t 	   	   rri l	  
t r 	   t	   ◦ 	  t 	   ◦ 	  
	   	   	  
is r 	   r	  t 	   ir 	   t 	  
i l	  i tr :	  	  	  
	  
i l	  i tr :	  	  
	   ll	  t 	   t i 	   	   s	   it 	  s s si 	  
t 	   f	   i i tr :	  	  
. 	  I 	   	   	  
t 	   f	   i i tr :	  	  
. 	  I 	   	  
i 	   	   :	  
	  
i 	   :	  
	  
S rc 	   f	  i f r a ;	  I iza 	   c 	   ali 	  ( .i iz . rg)	  i 	  c lla ra 	   it 	  t 	   a al	   lt	  a 	  I za	  I iza 	  S it	  
( . r v za. rg);	  acc ss 	  S t r	   ,	   .	   	   ;	   ( ): -­‐ .	  
	   	   i 	   	  f 	   i 	   	   	   	   	   	   	   	   	   	  i j 	   i ,	  
l 	   -­‐ 	   .	  
  	   	   i 	   	   	   	   	   	   	   	   	   i 	   f	   	   i 	   	  ( . .,	   l i )	   	  
	   i 	   	   f	   ,	   ,	   	   	   f	   i 	   .	  
  	   	   	   	   	   	   i l l .	   	   	   	   	   	   	   	   ,	   	  
	   ,	  f l 	   	   	   	   f	   	   	  l 	   	   	  l .	   i 	   l 	   	   	   	   	   	  
	   	   	   f	   .	  
  	   	   	   	   	  i 	   i .	   	   	   i 	   ll	   	   	   i 	   	  
	   	   i 	   	  if	   	   	  i 	   	   i 	  f 	   	   	   .	  If	   i 	   -­‐ 	  ( )	  
i 	   	   ,	   i 	   	   	   	   	   i 	   -­‐ .	  If	   i 	   -­‐ 	  ( )	   	   	   	   i 	  
	   	   	   i i .	   	   	   i 	   	   	   	   i l l .	  
I 	   i 	  I :	  
	  	  	  	   	  I 	   i 	   -­‐ -­‐ 	  	   -­‐ i 	   : 	   -­‐ : 	   	   	  
	   	   	   e 	  
	  ( 	   )	   	   	  ( 	   )	  	  
I	   	   	   l 	   	   li 	   i 	   	  
. l . i. i i 	  	  
i 	   i i . 	  	   -­‐ -­‐ -­‐ 	  
i r 	   rt	   	  r im r 	  f r	   t 	  t 	   t	   f	  t 	   i 	   it 	   i i tr 	  
	   	   I	  	   . i. i 	  	   -­‐ -­‐ 	  	   -­‐ -­‐ -­‐ 	  
i l 	   . ni l li . 	   -­‐ -­‐ -­‐ 	  
	   	   	   	   	  
f :	  
	  
. r i . 	  
a f :	  
	  
. r r . 	  
	   li :	  
. l	   i l 	   	   i l	  	  
l -­‐ 	  ( 	   	   i l)	  
	   li :	  
ll 	   i 	  
( 	   	   )	  
	   	   li :	  	  
f i t 	   	   i l	  	  
t 	   t	   	  t 	   	  
	   	   	  
i 	   	  t 	   i 	   t 	  
	   	   li :	  
f i t 	   	   i l	  
t 	   t	   	  t 	   	  
	   	   	  
i 	   	  t 	   i 	   t 	  
i l	  i :	  	  
	  
i l	   :	  
	   ll	  t 	   t i 	   	   o 	   it 	   i 	  
	   f	   i i :	  	  
. 	  I 	   	   	  
	   f	   i i :	  	  
. 	  I 	   	  
	   	   	  
	  
	   	  
	  
rc 	   f	  i f r ;	  I iz 	   c li 	  ( .i iz . r )	  i 	  c ll r 	   it 	  t 	   l	   lt	   	  I z 	  I iz 	   it	  
( . r z . r );	   cc ss 	   t r	   ,	   .	   	   ;	   ( ): -­‐ .	  
  	   	   i 	   	   	   i 	   	   	   	   	   	   	   	   	   	  i j 	   i ,	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   -­‐ 	   .	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a	   io o 	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   ,	   i 	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   ll 	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   i 	   l 	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   .	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   i .	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   i i 	   	  i 	   	   	  i 	   	   i 	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   -­‐ 	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   i 	   -­‐ 	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   i 	  
	   	   	   i i .	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   i l l .	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M 	  
. i . 	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. . 	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   i l	  	  
l -­‐ 	   	   	   i l 	  
	   li :	  
ll 	   i 	  
	   	   	  
	   	   li :	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   i l	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   i 	   	  
	   	   li :	  
i 	   	   i l	  
	   	   	   	   	  
	   	   	  
i 	   	   	   i 	   	  
i l	  i :	  	  	  
	  
i l	  in : 	  
	   ell	   	   n	   	   	   i 	   i 	  
	   	   i i :	  	  
. 	  I 	   	   	  
t 	   	   i i :	  	  
. 	  I 	   	  
	   	   	  
	  
	   	  
	  
r 	   f	  i f r ;	  I i 	   	   li 	  ( .i i . r )	  i 	   ll r 	   it 	  t 	   l	   lt	   	  I 	  I i 	   it	  
( . r . r );	   	   t r	   ,	   .	   	   ;	   ( ): -­‐ .	  
	   	   i 	   	   	   i 	   	   	   	   	   	   	   	   	   	  i 	   i 	  
l 	   -­‐ 	   	  
  	   	   i 	   	   	   	   	   	   	   	   	   i 	   	   	   i 	   	   	   l i 	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   i 	   	  
  	   	   i 	   	   	   	   i l 	   	   	   	   	   	   	   	   	   i 	  
	   	   ll 	   	   	   	   	   	   	  l 	   	   	  l 	   	   l 	   	   	   	   	   	  
	   	   	   	   	  
	   	   	   	   t 	  i 	   i 	   	   	   i 	   ll	   	   	   i 	   	  
	   	   i i 	   	  i 	   	   	  i 	   	   i 	   	   	   	   	   	   i 	   -­‐ 	   	  
i 	   	   	   i 	   	   	   	   e 	   i 	   -­‐ 	   	   i 	   -­‐ 	   	   	   	   	   i 	  
	   	   	   i i 	   	   n 	   i 	   	   	   	   i l l 	  
n 	   	   a 	  
	  	  	  	  Drug	  Informa>on	  Serv ces	  401-­‐874-­‐9188	  	  Monda -­‐F iday	   :30	  am-­‐4:0 	  pm	  EST	  
Pneumoc cal	  Vaccina>on	  I f rma>on	  Sheet	  
PCV13	  (Prevna 	  13®)	   nd	  PPSV23	  (Pneumovax®	  23)	  	  
RI	  Department	  of	  Health	  State	  Suppli d Va ci a7o 	  Pr gram	  
w .he lth.ri.gov resource /immuniza>o /	  	  
Medicare	  www.medicarenhic.c 	  	   -­‐866-­‐801-­‐5304	  
Medicare	  Part	  B	  reimburses	  fo 	  both	  the	  cost	  of	  the	  v ccine	  and	  its	  administraDon	  
BC S	  of	  RI	  	  www.bcbsri.com/providers	  	  4 1-­‐274-­‐48 	  	  1-­‐800-­‐230-­‐905 	  
UnitedHealthCare	   ww.unitedhe lthca onl .com	  1-­‐877-­‐842-­‐3210	  
	  PPSV23	  (Pneumovax®23)	   PCV13	  (Prevnar13®)	  
Manufact rer:	  
erck	  
ww . erckvaccines.com/	  
Manufact rer:	  
Pﬁze 	  
ww .pﬁz rpro.com/	  
Ho 	  Supplied:	  
0.5ml	  S ngle	  Dose	  Vial	  	  
Mul@-­‐Dose	  (5	  d se	  Vial)	  
Ho 	  Sup lied:	  
Preﬁlled	   yring 	  
(10	  p 	  P ckage)	  
Storage	  and	  Han ling:	  	  
Refrig rat 	  o 	  Arrival	  	  
Store	  at	  2◦C	   o	  8◦C	  
DO	   T	  FREEZE	  
Discard	  aYer	  the	  expir @on	  date	  
Storage	  and	  Handling:	  
Refrig rat 	  o 	  Arrival	  
Store	   t	  2◦C	   o	  8◦C	  
DO	  N T	  FREEZE	  
Discard	  aYer	  the	  expir @on	  date	  
Special	  instruc7ons:	  	  	  
None	  
Speci l	  instruc7ons:	  	  
Shak 	  wel 	  to	  obtain	  a	  homogeneous	  white	  suspension	  
Route	  of	  Administra7on:	  	  
0.5mL	  IM	   r	  SQ	  
Route	  o 	  Ad inistra7on:	  	  
0.5mL	  IM	  ONLY	  
Contrai dica>ons	  and	  Pr c > ns:	  
	  
Si e	  Eﬀ ct :	  
	  
Source	  of	  informa@on;	  I muniza@on	  Ac@on	  Co li@on	  (www.immunize.org)	  in	  c llabora@o 	  wit 	  the	  Na@o al	  Adult	  and	  Inﬂuenza	  Immuniza@on	  Summit	  
(www.p even@ ﬂuenza.org);	  accessed	  September	  4,	  2013.	  MMWR	  2012;	  61(40):816-­‐819.	  
•  Most	  co o 	  side	  eﬀ cts	  from	  either	  PPSV23	   	  PCV13	  ar 	  s re ss	  and	  re s 	  at	  the	  injec@on	  site,	  
las@ng	  1-­‐2	  days.	  
•  	  n t	  give	  PPSV23	  or	  PCV13	  to	  pa@ents	  wh 	   ave	  a	  hist ry	   f	  a	  serious	  reac@ n	  ( .g.,	  an phylaxi )	  aYer	  
a	  p vious	   os 	  of	  PCV13,	  PPSV,	  or	   	  of	  their	  compone ts.	  
•  	  n 	  give	  PPS 23	  an 	   C 13	  simultaneously.	  For	  pa@ents	   ho	  ne d	  bot 	  PCV13	  and	  PPSV23,	  give	  
PCV13	  ﬁrst,	  foll wed	  by	   	  d se	  of	  PPSV23	   t	  least	  8	  w k 	  l t r.	  Give	  adults	  PCV1 	   2	  months	  aYer	  th 	  
m st	  r c nt	  dose	   f	  P S 2 .	  
•  PCV13	  and	  PPSV23	  ar 	  both	  inac@ ated	  vacci s.	  You	   an	  give	  a l	   th r	  rec de 	  vaccina@ons	  at	  
the	  same	  visit	  EXCEPT	  if	  th 	   on	  is	   	  c didat 	  fo 	  MCV4	  and	  PCV13.	  If	  using	  MCV4-­‐D	  (Me actra®)	  
give	  PCV13	  ﬁrst,	  wait	  4	  weeks	  and	  th n	  giv 	  MCV4-­‐D.	  If	   sing	   CV4-­‐ RM	  ( enveo®)	  both	  can	  be	  given	  
at	  the	   ame	  visit.	  You	  cannot	  give PCV13	  and	  PPSV23	   imult n ously.	  
Insurance	  Carrier	  Inf rma> :	  
PCV13 and PPSV23 Indications for Adults ≥ 19 Years* by Risk Group 2,3
   PCV13 (Prevnar13®) PPSV23 (Pneumovax®23)
Risk Group     Underlying Medical Condition
       Recommended             Recommended            Revaccinate 5 years
                                 after first dose
Persons with normal Cigarette smoker  ✓
immune function
 Chronic heart disease†	 	 ✓
	 Chronic lung disease§  ✓ 
 Diabetes mellitus  ✓ 
 Cerebrospinal fluid leak ✓ 	 ✓ 
 Cochlear implant£ ✓ 	 ✓ 
 Alcoholism  ✓ 
 Chronic liver disease, cirrhosis  ✓ 
Persons with functional or Sickl  cell disease or other ✓ 	 ✓ 	 ✓ anatomical asplenia hemaglobinopathy∞ 
 Congenital or acquired asplenia∞ ✓ 	 ✓ 	 ✓ 
Immunocompromised Congenital or acquired ✓ 	 ✓ 	 ✓ persons immunodeficiency¶
 HIV infection ✓ 	 ✓ 	 ✓ 
 Chronic renal failure ✓ 	 ✓ 	 ✓ 
 Nephrotic syndrome ✓ 	 ✓ 	 ✓ 
 Leukemia ✓ 	 ✓ 	 ✓ 
 Lymphoma ✓ 	 ✓ 	 ✓ 
 Hodgkin disease ✓ 	 ✓ 	 ✓ 
 Generalized malignancy ✓ 	 ✓ 	 ✓ 
 latrogenic immunosuppression**
 (Both high and low level immunosuppression) 
✓ 	 ✓ 	 ✓ 
 Solid organ transplant ✓ 	 ✓ 	 ✓ 
 Multiple myelo a ✓ 	 ✓ 	 ✓ 
	 Hematopoietic stem cell transplant Please refer to reference 3 for specific guidance
(Please refer to reference 3 for 
specific guidance.)
(Please refer to reference 3 for 
specific guidance.)
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Preﬁll d	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Stor ge	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Source	   f	  infor a@on;	  I uniza@on	  Ac@on	  Coali@on	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  in	  collab ra@o 	   ith	  the	  Na@o al	  Adult	  a d	  Inﬂuenza	  I uniza@on	  Su it	  
( .preven@nﬂuenza.org);	  access d	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  4,	  2013.	   R	   012;	  61(40):816-­‐819.	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   f	  t ir	  c ts.	  
	   t	   iv 	   S 	   	   	  si lt sly.	  F r	   nts	   	   	   t 	   	   d	   S ,	   iv 	  
	   rst,	  f ll 	   y	   	   se f	   S 	   t	  l t	   	   ks	  l t r.	   iv 	   lts	   	   	   t s	   r	  t 	  
st	  r c t	   s f	   S .	  
•  	  a 	   S 	   r 	   t 	  i c v t 	  v ci s.	   	   iv 	   ll	   t r	  r c 	  v cci s	   t	  
t 	  s 	  vi it	   	  if	  t 	   r 	  is	   	  c t 	  f r	   	   	   .	  If	   si 	   -­‐ 	  ( ctr )	  
iv 	   	   rst,	   it	   	   k 	   	  t 	   iv 	   -­‐ .	  If	   i 	   -­‐ 	  ( v )	   t 	  c 	   	   iv 	  
t	  t 	  s 	  vi it.	   	   	   iv 	   	   S 	   i lt sly.	  
I r 	   rri r	  I f r :	  
† Including congestive heart failure and cardiomyopathies, excluding hypertension.
£ If feasible, administer PCV13 and PPSV23 ≥ 2 weeks before planned cochlear implant surgery at appropriate intervals as described in the algorithm on the front page.
∞ For PPSV23 naive patients planning splenectomy: Give PCV13; wait at least 8 weeks then give PPSV23. Do not give PPSV23 within 2 weeks of planned splenectomy.
§ Including chronic obstructive pulmonary disease, emphysema, and asthma.
¶ Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies (particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding chronic granulomatous disease).
** Those requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation.
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Facts About Pneumococcal Disease:
• Streptococcus pneumoniae bacteria (i.e., pneumococci) are usually found in the upper respiratory tract of 
 most people.
• Pneumococcal disease most commonly presents as a serious infection in the lungs (pneumonia), blood 
 (bacteremia), or brain (meningitis). The annual U.S. case estimate for invasive pneumococcal disease 
 (bacteremia and/or meningitis) is 40,000 and 4,250 deaths.
• Pneumococcal disease most often occurs in older people as well as in people with a predisposing condition
 (e.g., immunosuppression, pulmonary disease, heart disease, diabetes). The disease rates for adults in 
 these groups can be more than 20 times those for adults without high-risk medical conditions. 
• PPSV23 is 60–70% effective in preventing serious pneumococcal disease; it does not provide substantial 
 protection against all types of pneumonia (viral and bacterial). It is not a “pneumonia” vaccine.
Frequently Asked Questions:
Question: Can I get the influenza and pneumococcal vaccines at the same time?
Yes. These vaccines can be given at the same time. If giving two IM vaccinations, separate by one inch in the 
body muscle to reduce likelihood of local reactions overlapping.  
Question: If patients who are in a recommended risk group for PPSV23 or PCV13 aren’t sure if they 
have previously received these vaccines, should healthcare providers vaccinate them?
Yes. If patients do not have a documented vaccination history for these two vaccines and their records are not 
readily obtainable, you should administer the recommended doses. Extra doses will not cause harm to the 
patient.
Question: Is an egg allergy a contraindication for PCV13 or PPSV23? 
No. Both vaccinations are safe for persons with egg allergies.
Question: If my state has a registry, do I still need to give patients vaccine record cards?
Yes. Patient-held cards are an extremely important part of a person’s medical history. The person may move 
to an area without a registry, and a personal record may be the only vaccination record available. In addition, 
even within a state, all healthcare providers may not participate in the registry, and the personal record card 
would be needed.
Question: My patient has had laboratory-confirmed pneumococcal pneumonia. Does he/she still need 
to be vaccinated with PPSV23?
Yes. There are more than 90 known serotypes of pneumococcus (23 serotypes are in the current vaccine). 
Infection with one serotype does not necessarily produce immunity to other serotypes.  As a result, if the 
person is a candidate for vaccination, he/she should receive it even after one or more episodes of invasive 
pneumococcal disease.
Question: Why is pneumococcal vaccination recommended for smokers and asthmatics?
In 2008, the Advisory Committee on Immunization Practices (ACIP) reviewed new information that suggests 
that asthma is an independent risk factor for pneumococcal disease among adults. ACIP also reviewed new 
information that demonstrates an increased risk of pneumococcal disease among smokers. Consequently, 
ACIP recommends to include both asthma and cigarette smoking as risk factors for pneumococcal disease 
among adults age 19 through 64 years and as indications for PPSV23.
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PCV13 (Prevnar13®)
Manufacturer:
Pfizer
http://www.pfizerpro.com/hcp/prevnar13
How Supplied:
Prefilled Syringe
(10 per Package)
Storage and Handling:
Refrigerate on Arrival
Store at 2◦C to 8◦C
DO NOT FREEZE
Discard after the expiration date
Special instructions: 
Shake well to obtain a homogeneous white suspension
Route of Administration: 
0.5mL IM ONLY
PPSV23 (Pneumovax®23)
Manufacturer:
Merck
www.merckvaccines.com/Products/Pneumovax/Pages/home
How Supplied:
0.5mL Single Dose Vial 
Multi-Dose (5 dose Vial)
Storage and Handling: 
Refrigerate on Arrival 
Store at 2◦C to 8◦C
DO NOT FREEZE
Discard after the expiration date
Special instructions:  
None
Route of Administration: 
0.5mL IM or SQ
Insurance Carrier Information:
Medicare  www.medicarenhic.com   1-866-801-5304*
BCBS of RI   www.bcbsri.com/providers   401-274-4848  1-800-230-9050
UnitedHealthCare  www.unitedhealthcareonline.com  1-877-842-3210
RI Department of Health State Supplied Vaccination Program  www.health.ri.gov/resources/immunization/ 
Contraindications and Precautions:
• Do not give PPSV23 or PCV13 to patients who have a history of a serious reaction (e.g., anaphylaxis) after  
 a previous dose of PCV13, PPSV23, or one of their components.
• Do not give PPSV23 and PCV13 simultaneously. For vaccine naive patients, give PCV13 first, followed by a  
 dose of PPSV23 ≥ 1 year† (unless patient in a population specified by ACIP to require shorter interval, see
 page 1). For patients who have already received PPSV23, give PCV13 12 months after the most recent 
 dose of PPSV23.
• Vaccine Co-administration: (1) all vaccines used for routine vaccination in the United States can be given on 
 the same day; (2) an inactivated vaccine can be administered either on the same day as or at any time  
 before or after another inactivated or a live vaccine; and (3) any 2 LIVE vaccines that are not given on the  
 same day must be spaced at least 4 weeks apart. Zoster vaccine is a live, attenuated vaccine; injectable  
 influenza vaccine and pneumococcal polysaccharide vaccine are inactivated vaccines. So these 3 vaccines  
 can be given on the same day or at any time before or after each other. They should be given as separate  
 injections, not combined in the same syringe.
Side Effects:
• Most common side effects from either PPSV23 or PCV13 are soreness and redness at the injection site,  
 lasting 1-2 days.
Drug Information Services 401-874-9188     Monday-Friday 8:30 am - 4:00 pm EST
* An initial pneumococcal vaccine may be administered to all Medicare beneficiaries who have never received a pneumococcal vaccine under Medicare Part B. A different, second 
 pneumococcal vaccine may be administered 1 year after the first vaccine was administered (i.e., 11 full months have passed following the month in which the last pneumococcal vaccine
 was administered). Please note that the “interval” between the two different pneumococcal vaccines must be at least 11 full months or greater for Medicare reimbursement, not the 
 shorter “interval” recommended for specific populations identified by ACIP. 
 Acquired from www.immunize.org on September 4, 2013. We thank the Immunization Action Coalition. 
† Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee in Immunization Practice (ACIP)
 MMWR Morb Mortal Wkly Rep. 2015; 64(34): 944-947.
